0512-67998889(Suzhou)
18051093220(Shenzhen)
The Road Ahead is Long Yet Bright / RocRock Biotech Completes the Construction of its Adenovirus Suspension Process Platform Recently, RocRock Biotech Co., Ltd. (hereinafter referred to as RocRock Biotech) announced the completion of its clinical-grade adenovirus suspension process platform. This significant milestone marks the reaffirmation of RocRock Biotech's capabilities in the fields of cell therapy and gene therapy and lays a solid foundation for the company's future development of disruptive new products and market expansion. Adenoviruses are a common type of virus with a broad application prospect in gene therapy, cell therapy, and vaccine development. However, traditional adenovirus production processes suffer from high costs, low yields, and unstable quality, which limits their promotion in clinical applications. To address these issues, RocRock Biotech has spent a year independently developing its adenovirus suspension platform process, optimizing the production process and enhancing technological levels to achieve efficient and stable production of adenoviruses.
Our company's process platform utilizes internationally leading technology and equipment, such as the Cytiva Wave 25, AKTA Pure 150, and KR2i ultrafiltration system. We strictly control every
step, from cell proliferation and virus cultivation to virus purification and quality control, ensuring that each batch of adenoviral vectors meets the highest global standards. In addition, RocRock
Biotech has a dedicated team of professionals who not only possess extensive experience but also maintain a passion and pursuit for biotechnology.
After multiple rounds of experimental validation, the adenoviruses produced by this process have exceeded the expected targets in terms of purity and titer, with impurities far below platform
standards and good stability. Moreover, the process is characterized by its simplicity, low cost, and short cycle time, making it highly valuable for practical application and promotion. The
unique adenoviral formulation developed by RocRock Biotech can withstand three freeze-thaw cycles at -80°C and still achieve a live virus titer of over 11 logs, which is the highest known
cost-performance ratio globally. The patent for this process is also in the application process.
In the future, RocRock Biotech will continue to increase R&D investment, expand its product pipeline, and promote more innovative therapies into clinical applications for the benefit of patients.
At the same time, the company will actively seek project cooperation and technical exchanges with industry partners to jointly promote the thriving development of the cell and gene therapy
(CGT) industry.
0512-67998889(Suzhou)
18051093220(Shenzhen)
Cathy.Lv@rocrockbio.com(Suzhou)
lliangjing@rocrockbio.com (Shenzhen)